Crescent Biopharma Inc. has announced a series of leadership appointments as it bolsters its team with experienced professionals in oncology drug development and biotech operations. Joshua Brumm has been named chief executive officer and joins the board of directors, while Jonathan McNeill, M.D., takes on the role of president and chief operating officer. Ellie Im, M.D., has been appointed chief medical officer, Rick Scalzo, MBA, as chief financial officer, Jan Pinkas, Ph.D., as chief scientific officer, Amy Reilly as chief communications officer, and Tanya Sengupta, MBA, as executive vice president, chief of strategy and operations. Additionally, David Lubner has joined the board of directors. These changes are part of Crescent's strategy to advance its therapeutic pipeline for solid tumors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。